Results 41 to 50 of about 34,807 (281)
Pharmacogenetics of Asthma [PDF]
American Journal of Respiratory and Critical Care Medicine, 2002 Recent advances in the extent of knowledge regarding interindividual genetic variation in drug treatment targets and drug metabolizing enzymes has resulted in studies designed to assess the contribution of genetic variability to treatment response in a range of diseases. This review describes the current state of knowledge of genetic variability in key
Lyle J, Palmer +3 more
openaire +4 more sources
Systematic identification of non-coding pharmacogenomic landscape in cancer
Nature Communications, 2018 In this study the authors build lncRNA-drug response models for 265 anti-cancer agents across 27 cancer types. They report their cancer cell line based lncRNA EN-models are able to effectively predict therapeutic outcome for breast cancer, ovarian cancer,
Yue Wang +6 more
doaj +1 more source
Integrating rare genetic variants into pharmacogenetic drug response predictions
Human Genomics, 2018 Background Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions.
Magnus Ingelman-Sundberg +3 more
doaj +1 more source
miRNAs as Key Players in the Management of Cutaneous Melanoma
Cells, 2020 The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso +4 more
doaj +1 more source
Pharmacogenetics of OPRM1 [PDF]
Pharmacology Biochemistry and Behavior, 2014 Pharmacogenetic research has the potential to explain the variation in treatment efficacy within patient populations. Understanding the interaction between genetic variation and medications may provide a method for matching patients to the most effective therapeutic options and improving overall patient outcomes.
Richard C, Crist, Wade H, Berrettini
openaire +2 more sources
Warfarin pharmacogenetics [PDF]
Trends in Cardiovascular Medicine, 2015 The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes have been strongly and consistently associated with warfarin dose requirements, and dosing algorithms incorporating genetic and clinical information have been shown to be predictive of stable warfarin dose.
Julie A, Johnson, Larisa H, Cavallari
openaire +2 more sources
Pharmacogenetics and clinical gastroenterology [PDF]
, 2003 Many drugs exhibit variable efficacy and toxicity. Pharmacogenetics explores the genetic underpinnings of variable drug response. Pharmacogenetic testing is beginning to enter the clinic and will have a significant impact on the practice of clinical ...
Givens, Raymond C., Watkins, Paul B.
core +1 more source
Advanced Science, EarlyView.ALDH2, which is overexpressed in multiple myeloma, competitively binds KEAP1 to stabilize NRF2 by blocking its ubiquitin‐proteasomal degradation. Stabilized NRF2 translocates into the nucleus to upregulate the expression of GPX4. In parallel, NRF2 binds to the ALDH2 promoter to regulate its transcription, forming a positive feedback loop that represses
Ruonan Shao +10 more
wiley +1 more source
BMC Medicine, 2019 Background Pharmacogenetics (PGx) is currently implemented in hospitals to optimize therapy with high-risk drugs. However, many drugs with dosing recommendations from the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics ...
P. C. D. Bank +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source